PicoCELA Inc. (NASDAQ:PCLA) Short Interest Up 29,900.8% in December

PicoCELA Inc. (NASDAQ:PCLA) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 3,625,291 shares, a growth of 29,900.8% from the December 15th total of 12,084 shares. Based on an average daily volume of 110,555,509 shares, the days-to-cover ratio is presently 0.0 days. Approximately 13.3% of the shares of the stock are sold short. Approximately 13.3% of the shares of the stock are sold short. Based on an average daily volume of 110,555,509 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

PicoCELA Stock Down 6.5%

Shares of PCLA traded down $0.02 during mid-day trading on Monday, hitting $0.25. 1,330,513 shares of the stock were exchanged, compared to its average volume of 2,166,882. PicoCELA has a 52-week low of $0.12 and a 52-week high of $9.80. The firm has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.57.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned about 0.16% of PicoCELA at the end of the most recent reporting period.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.